HUP0204291A2 - Hormonpótlási terápiához alkalmazható készítmény, amely drospirenont és ösztrogént tartalmaz - Google Patents

Hormonpótlási terápiához alkalmazható készítmény, amely drospirenont és ösztrogént tartalmaz

Info

Publication number
HUP0204291A2
HUP0204291A2 HU0204291A HUP0204291A HUP0204291A2 HU P0204291 A2 HUP0204291 A2 HU P0204291A2 HU 0204291 A HU0204291 A HU 0204291A HU P0204291 A HUP0204291 A HU P0204291A HU P0204291 A2 HUP0204291 A2 HU P0204291A2
Authority
HU
Hungary
Prior art keywords
estrogen
drospirenone
hormone replacement
preparation
composition containing
Prior art date
Application number
HU0204291A
Other languages
English (en)
Inventor
Wolfgang Heil
Jürgen Hilmann
Ralph Lipp
Rolf Schürmann
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26071749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0204291(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of HUP0204291A2 publication Critical patent/HUP0204291A2/hu
Publication of HUP0204291A3 publication Critical patent/HUP0204291A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgya gyógyászati készítmény, amely első hatóanyagkéntösztrogént, előnyösen ösztradiolt vagy ösztradiol-valerátot tartalmazelegendő mennyiségben nők hiányos endogén szintű ösztrogénjévelkapcsolatos betegségek, tünetek vagy rendellenességek kezelésére ésmásodik hatóanyagként 6b,7b,15b,16b-dimetilén-3-oxo- 17alpha-preg-4-én-21,17-karbolaktont (drospirenont, DRSP) elegendő mennyiségben azendometrium ösztrogén káros hatásainak megvédésére. A szer többekközött a perimenopauzális, menopauzális és posztmenopauzális nőkkezelésére, alkalmas. A készítmény hormonpótlásra használható éstöbbfázisú készítményként adagolható. A kombinációs terápia a DRSP ésösztrogén folyamatos, egymás utáni és megszakított adagolásával vagyezek kombinálásával történhet és mindkét hatóanyag adott esetbenmikronizált formában lehet. Ó
HU0204291A 2000-01-18 2001-01-18 Use of composition containing estrogen and drospirenone for hormone replacement therapy HUP0204291A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48402600A 2000-01-18 2000-01-18
EP00200183 2000-01-18
PCT/IB2001/000041 WO2001052857A1 (en) 2000-01-18 2001-01-18 Drospirenone for hormone replacement therapy

Publications (2)

Publication Number Publication Date
HUP0204291A2 true HUP0204291A2 (hu) 2003-04-28
HUP0204291A3 HUP0204291A3 (en) 2003-05-28

Family

ID=26071749

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0204291A HUP0204291A3 (en) 2000-01-18 2001-01-18 Use of composition containing estrogen and drospirenone for hormone replacement therapy

Country Status (30)

Country Link
EP (2) EP1257280B1 (hu)
JP (2) JP5128743B2 (hu)
KR (2) KR100913910B1 (hu)
CN (2) CN1395488A (hu)
AT (2) ATE442147T1 (hu)
AU (3) AU2001225413B2 (hu)
BG (1) BG65849B1 (hu)
BR (1) BR0107683A (hu)
CA (1) CA2394165C (hu)
CY (1) CY1109567T1 (hu)
CZ (1) CZ20022411A3 (hu)
DE (2) DE60113809T2 (hu)
DK (2) DK1611892T3 (hu)
EE (1) EE05533B1 (hu)
ES (2) ES2332226T3 (hu)
HK (2) HK1047248B (hu)
HU (1) HUP0204291A3 (hu)
IL (3) IL150775A0 (hu)
ME (1) ME00292B (hu)
MX (1) MXPA02006613A (hu)
NO (1) NO335570B1 (hu)
NZ (1) NZ520630A (hu)
PL (1) PL201878B1 (hu)
PT (1) PT1611892E (hu)
RS (1) RS52149B (hu)
RU (2) RU2275198C2 (hu)
SI (2) SI1611892T1 (hu)
SK (2) SK287719B6 (hu)
WO (1) WO2001052857A1 (hu)
ZA (2) ZA200206551B (hu)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4354667B2 (ja) * 1999-08-31 2009-10-28 バイエル・シエーリング・ファーマ・アクチエンゲゼルシャフト 避妊薬としての使用へのエチニルエストラジオールとドロスピレノンの医薬用組合せ
EP1216713A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions of estrogen-cyclodextrin complexes
WO2003006027A1 (en) 2001-07-13 2003-01-23 Schering Aktiengesellschaft Combination of drospirenone and an estrogen sulphamate for hrt
ES2269999T3 (es) * 2002-03-11 2007-04-01 Janssen Pharmaceutica N.V. Terapia hormonal sustitutiva que inhibe progestageno sulfatasa continua.
BR0309780A (pt) * 2002-04-26 2005-03-22 Schering Aktiengellschaft Tratamento da hipertensão em mulheres recebendo terapia de reposição hormonal
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
WO2004041289A1 (en) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Cardiovascular protection using anti-aldosteronic progestins
AU2002368326A1 (en) * 2002-11-05 2004-06-07 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
EA012570B1 (ru) * 2004-03-10 2009-10-30 Шеринг Акциенгезельшафт Твердая или полутвердая композиция, содержащая молекулярно диспергированный дроспиренон, и способ ее получения
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
DE102004023984A1 (de) * 2004-05-14 2005-12-08 Hf Arzneimittelforschung Gmbh Filmförmiges, oral zu verabreichendes Arzneimittel, enthaltend Estriol
US8022053B2 (en) 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
US20090181075A1 (en) * 2005-07-15 2009-07-16 Gordon Ryan D Drospirenone containing transdermal drug delivery devices and methods of delivery thereof
DE102005056527A1 (de) * 2005-11-25 2007-07-12 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
CN101623287B (zh) * 2008-07-07 2012-02-08 天津金耀集团有限公司 一种屈螺酮类似物的治疗更年期综合症的药物组合物
ES2344675B1 (es) * 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
ES2533584T3 (es) * 2010-04-15 2015-04-13 Bayer Intellectual Property Gmbh Formas de dosificación oral sólidas de dosis baja para TSH
CA2795801C (en) * 2010-04-15 2018-05-29 Bayer Intellectual Property Gmbh Very low-dosed solid oral dosage forms for hrt
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
KR20140088197A (ko) 2011-11-04 2014-07-09 바이엘 파마 악티엔게젤샤프트 18-메틸-6,7-메틸렌-3-옥소-17-프레그느-4-엔-21,17β-카르보락톤, 상기 화합물을 함유하는 약제학적 제제 및 자궁내막증 치료에 있어서 이들의 용도
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
GEP20217243B (en) 2015-06-18 2021-04-26 Sprl Estetra Orodispersible dosage unit containing an estetrol component
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
US11253498B2 (en) 2017-06-01 2022-02-22 Nexyon Biotech Co., Ltd. Pharmaceutical composition for treatment of bone-related disease
JOP20200260A1 (ar) * 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
JPH07114946B2 (ja) * 1988-10-24 1995-12-13 株式会社奈良機械製作所 難溶性物質の処理方法
JP2859919B2 (ja) * 1990-03-15 1999-02-24 旭化成工業株式会社 難溶性薬物の溶出性改善方法
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
JPH07112928A (ja) * 1993-10-15 1995-05-02 Freunt Ind Co Ltd 難溶性薬物の溶解性改善方法およびそれにより得られた粒状薬剤
JP4022269B2 (ja) * 1995-05-26 2007-12-12 協和醗酵工業株式会社 医薬組成物
US5897539A (en) * 1995-09-28 1999-04-27 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
CN1186024C (zh) * 1996-07-26 2005-01-26 惠氏公司 单阶段避孕方法和含有黄体酮和雌激素组合物的避孕药盒
DE19633685C1 (de) * 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
JPH10182701A (ja) * 1996-12-26 1998-07-07 Sanei Toka Kk 溶出性向上粉末及びその製造方法
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
JP4354667B2 (ja) * 1999-08-31 2009-10-28 バイエル・シエーリング・ファーマ・アクチエンゲゼルシャフト 避妊薬としての使用へのエチニルエストラジオールとドロスピレノンの医薬用組合せ

Also Published As

Publication number Publication date
EP1257280B1 (en) 2005-10-05
RU2402331C2 (ru) 2010-10-27
RU2005140938A (ru) 2007-07-10
NZ520630A (en) 2004-09-24
IL191131A0 (en) 2008-11-03
PL201878B1 (pl) 2009-05-29
CN1395488A (zh) 2003-02-05
RU2275198C2 (ru) 2006-04-27
JP2009120615A (ja) 2009-06-04
AU2005209600B2 (en) 2008-08-07
AU2541301A (en) 2001-07-31
KR100747965B1 (ko) 2007-08-08
NO335570B1 (no) 2014-12-29
IL191131A (en) 2010-12-30
ZA200601285B (en) 2008-01-08
CY1109567T1 (el) 2014-08-13
SI1611892T1 (sl) 2010-01-29
ZA200206551B (en) 2006-04-29
JP5563227B2 (ja) 2014-07-30
YU54602A (sh) 2006-01-16
KR100913910B1 (ko) 2009-08-26
JP5128743B2 (ja) 2013-01-23
BG106915A (bg) 2003-04-30
DE60139907D1 (de) 2009-10-22
HK1082433A1 (en) 2006-06-09
ATE305789T1 (de) 2005-10-15
DE60113809D1 (de) 2006-02-16
EP1611892A3 (en) 2006-02-01
CN101934078A (zh) 2011-01-05
PT1611892E (pt) 2009-11-20
MEP38008A (en) 2011-02-10
SI1257280T1 (sl) 2006-02-28
NO20022966L (no) 2002-09-18
EP1257280A1 (en) 2002-11-20
JP2003520239A (ja) 2003-07-02
ES2247054T3 (es) 2006-03-01
ATE442147T1 (de) 2009-09-15
IL150775A0 (en) 2003-02-12
DK1611892T3 (da) 2009-11-02
SK10322002A3 (sk) 2003-03-04
EE200200401A (et) 2003-10-15
AU2001225413B2 (en) 2005-06-23
CA2394165C (en) 2010-04-13
PL356987A1 (en) 2004-07-12
RU2002122113A (ru) 2004-03-10
NO20022966D0 (no) 2002-06-20
SK287719B6 (en) 2011-07-06
WO2001052857A1 (en) 2001-07-26
HK1047248A1 (en) 2003-02-14
AU2005209600A1 (en) 2005-09-29
ME00292B (me) 2011-05-10
EE05533B1 (et) 2012-04-16
EP1611892B1 (en) 2009-09-09
KR20020088066A (ko) 2002-11-25
CA2394165A1 (en) 2001-07-26
ES2332226T3 (es) 2010-01-29
IL150775A (en) 2008-08-07
EP1611892A2 (en) 2006-01-04
SK288129B6 (sk) 2013-10-02
HUP0204291A3 (en) 2003-05-28
RS52149B (sr) 2012-08-31
BR0107683A (pt) 2002-11-12
KR20070051956A (ko) 2007-05-18
CZ20022411A3 (cs) 2003-02-12
HK1047248B (zh) 2005-12-30
MXPA02006613A (es) 2003-10-15
DE60113809T2 (de) 2006-06-22
DK1257280T3 (da) 2005-12-12
BG65849B1 (bg) 2010-03-31

Similar Documents

Publication Publication Date Title
HUP0204291A2 (hu) Hormonpótlási terápiához alkalmazható készítmény, amely drospirenont és ösztrogént tartalmaz
JP6153967B2 (ja) 延長されたホルモン避妊法における破綻出血の管理
US20050113350A1 (en) Extended use combination comprising estrogens and progestins
AR031563A1 (es) Una composicion farmaceutica para emplear en el tratamiento de trastornos menopausicos o posmenopausicos de estrogenos y acetato de medroxiprogesterona, una unidad de dosificacion farmaceutica y uso de una combinacion de estrogenos conjugados y acetato de medroxiprogesterona para la manufactura de u
US20080234240A1 (en) Extended Use Combination Comprising Estrogens And Progestins
KR20090080989A (ko) 여성 리비도의 유지 및/또는 증가를 위한 경구 치료요법을 위한 디에노게스트와 조합된 에스트라디올 발레레이트 또는 17β-에스트라디올의 용도
CA2267743A1 (en) Low dose estrogen interrupted hormone replacement therapy
EA200301022A1 (ru) Гормональная заместительная терапия
ES2310293T3 (es) Tratamiento o prevencion de sangrados no programados en mujeres bajo medicacion que contiene progestogeno.
MY128482A (en) New hormonal composition and its use
ES2293215T3 (es) Uso de una combinacion de un inhibidor de aromatasa, un progestageno y un estrogeno para el tratamiento de endometriosis.
WO2008122439A2 (en) Dr0spiren0ne/17beta-estradi0l regimen, pharmaceutical combination product and kit for performing this regimen
CA2248841C (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
ES2316402T3 (es) Mesoprogestagenos (moduladores de los receptores de progesterona) como un componente de composiciones para la hormonoterapia restitutiva (hrt).
HRP20070360B1 (hr) Drospirenon za hormonsku nadomjesnu terapiju
HRP20020666A8 (en) Drospirenone for hormone replacement therapy
TH134365B (th) โดรสไพริโนนสำหรับการรักษาด้วยการแทนที่ฮอร์โมน
AU2003206424B2 (en) Sequential estrogen/progesterone antagonist combination for hormone replacement therapy
US20080280861A1 (en) Method of Female Contraception and a Kit For Use Therein
AU3662300A (en) Use of sex hormones to obtain a nasal pharmaceutical composition that is useful in the treatment of undesirable uterine bleeding
KR20010110807A (ko) 조합 치료에서의 항프로게스타겐의 용도
TH134365A (th) โดรสไพริโนนสำหรับการรักษาด้วยการแทนที่ฮอร์โมน
MXPA98007513A (en) Sequencial combination of estrogen / antagonist of progesterone for therapy of replacement of hormo
MXPA06006031A (en) Extended use combination comprising estrogens and progestins

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE

Free format text: FORMER OWNER(S): SCHERING AKTIENGESELLSCHAFT, DE

FH91 Appointment of a representative

Free format text: FORMER REPRESENTATIVE(S): S.B.G. & K. SZABADALMI UEGYVIVOEI IRODA, HU

Representative=s name: DANUBIA SZABADALMI ES JOGI IRODA KFT., HU

FH92 Termination of representative

Representative=s name: S.B.G. & K. SZABADALMI UEGYVIVOEI IRODA, HU

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished